Altimmune, Inc. (NASDAQ:ALT) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 36.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,060 shares of the company’s stock after buying an additional 12,624 shares during the quarter. SG Americas Securities LLC owned about 0.07% of Altimmune worth $339,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Larson Financial Group LLC purchased a new stake in Altimmune in the 3rd quarter worth approximately $31,000. 180 Wealth Advisors LLC purchased a new position in Altimmune during the fourth quarter worth approximately $78,000. Stifel Financial Corp boosted its holdings in shares of Altimmune by 77.4% in the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares during the last quarter. Creative Planning boosted its holdings in shares of Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after purchasing an additional 3,132 shares during the last quarter. Finally, Centiva Capital LP acquired a new stake in shares of Altimmune during the 3rd quarter worth $120,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ALT has been the topic of a number of research analyst reports. UBS Group assumed coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Wednesday, January 22nd. Finally, Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $20.83.

Altimmune Stock Up 3.1 %

Shares of NASDAQ ALT opened at $6.64 on Wednesday. The business has a 50 day moving average price of $7.70 and a two-hundred day moving average price of $7.17. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The firm has a market cap of $472.24 million, a PE ratio of -4.28 and a beta of 0.19.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the previous year, the business posted ($0.39) EPS. On average, analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.